InspireMD (NYSE:NSPR) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a research report issued to clients and investors on Sunday. The firm set a “sell” rating on the stock.

A number of other equities analysts have also recently commented on NSPR. Piper Sandler reissued an “overweight” rating and issued a $4.50 price objective on shares of InspireMD in a research note on Tuesday, September 17th. Lake Street Capital began coverage on InspireMD in a research report on Wednesday, December 11th. They issued a “buy” rating and a $5.00 price target for the company.

InspireMD Trading Up 2.2 %

Shares of NSPR stock opened at $2.77 on Friday. The stock has a market capitalization of $72.25 million, a price-to-earnings ratio of -3.69 and a beta of 0.99. InspireMD has a 12-month low of $1.81 and a 12-month high of $3.42. The stock’s 50-day moving average price is $2.75 and its 200-day moving average price is $2.70.

InspireMD (NYSE:NSPR) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.04. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. The business had revenue of $1.81 million for the quarter, compared to analysts’ expectations of $1.74 million. During the same period in the prior year, the firm earned ($0.15) EPS. As a group, research analysts predict that InspireMD will post -0.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in InspireMD stock. Parkman Healthcare Partners LLC bought a new position in InspireMD, Inc. (NYSE:NSPR) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 104,081 shares of the company’s stock, valued at approximately $279,000. Parkman Healthcare Partners LLC owned about 0.42% of InspireMD at the end of the most recent quarter. Institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.